<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970472</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0070</org_study_id>
    <nct_id>NCT04970472</nct_id>
  </id_info>
  <brief_title>Bio Clinical Collection of Urothelial Carcinoma</brief_title>
  <acronym>MicroBlad</acronym>
  <official_title>Bio Clinical Collection of Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to collect tumor samples, urines, stool and blood from patients&#xD;
      with urothelial carcinoma. These samples will be stored in a secure and confidential&#xD;
      laboratory of the Toulouse University Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have shown that the bladder also harbors friendly bacteria that are&#xD;
      collectively called the microbiome. While the effect of the bladder microbiome to health&#xD;
      remains to be more clearly understood, an imbalance in the microbiome is associated with&#xD;
      several urinary diseases including overactive bladder and bladder cancer. But whether the&#xD;
      microbiome affects the outcome of Bacille Calmette et Gu√©rin (BCG)-immunotherapy or&#xD;
      chemotherapy in bladder cancer is still not known.&#xD;
&#xD;
      Researchers at Toulouse University Hospital want to learn as much as possible about bladder&#xD;
      cancer. One way to do so is by studying what is in your urines, blood, stool, saliva and in&#xD;
      your tumor.&#xD;
&#xD;
      Patients, who will be agree to take part in this study, will have at least about one&#xD;
      tablespoon of blood (as a residual of current biological analysis), 1 container of urines,&#xD;
      stool and saliva collected before bladder resection.&#xD;
&#xD;
      After transurethral bladder resection or radical cystectomy scheduled as part of the standard&#xD;
      of care, some tumor samples might be collected either as fresh tissue or as paraffin embedded&#xD;
      tissue and store in a secure and confidential laboratory at Toulouse University Hospital.&#xD;
&#xD;
      The patient's follow up will be schedule as the standard of care and no additional visit will&#xD;
      be required for the study. Oncological outcome of each patient will be recorded up to 5 years&#xD;
      This is an investigational study in which up to 500 patients will take part in the&#xD;
      collection. All patients will be all enrolled at Toulouse University Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">July 14, 2031</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.</measure>
    <time_frame>Day 0</time_frame>
    <description>Transcriptomic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.</measure>
    <time_frame>during the intervention/procedure/surgery</time_frame>
    <description>Transcriptomic, proteomic and epigenetic analysis</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>patients with Urothelial bladder carcinoma</arm_group_label>
    <description>collection of blood, urines, stool and tumor samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collection of blood, urines, stool and tumor samples</intervention_name>
    <description>blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.</description>
    <arm_group_label>patients with Urothelial bladder carcinoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, stool, blood and saliva samples will be stored. Tumor samples, collected for primary&#xD;
      cares using a punch knife, or a small surgery, will be stored.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will be all enrolled at Toulouse University Hospital during primary cares.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult &gt;18 years old&#xD;
&#xD;
          -  Patient with suspected or diagnosed Urothelial carcinoma&#xD;
&#xD;
          -  Patients who are willing to consent for this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Patients under 18 years old&#xD;
&#xD;
          -  Patients under guardianship or curators&#xD;
&#xD;
          -  Patients unable to sign a free and informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu Roumiguie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Roumiguie, MD, PhD</last_name>
    <phone>561323229</phone>
    <phone_ext>0033</phone_ext>
    <email>roumiguie.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rangueil University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu Roumiguie, MD, PhD</last_name>
      <phone>561323229</phone>
      <phone_ext>0033</phone_ext>
      <email>roumiguie.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial Carcinoma</keyword>
  <keyword>neoplasm</keyword>
  <keyword>bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

